Food Science and Biotechnology

, Volume 27, Issue 3, pp 853–857 | Cite as

Effect of Lactobacillus gasseri BNR17 on irritable bowel syndrome: a randomized, double-blind, placebo-controlled, dose-finding trial

  • Ji Yeon Kim
  • Yeo Jin Park
  • Hyo Jin Lee
  • Min Young Park
  • Oran KwonEmail author


Lactobacillus gasseri BNR17 is a strain isolated from human breast milk. The objective of this randomized, double-blind, placebo-controlled, and preliminary dose-finding trial was to find the effective dose and evaluate the effect of Lb. gasseri BNR17 on irritable bowel syndrome (IBS) symptoms. A total of 55 volunteers aged over 20 years with body mass index over 23 kg/m2 were randomized to intake a placebo, low-dose (BNR-L, 2 × 108 CFU/day), intermediate-dose (BNR-M, 2 × 109 CFU/day), or high-dose BNR (BNR-H, 2 × 5 × 109 CFU/day) for four weeks. Questionnaire for IBS symptoms scores and Lb. gasseri BNR17 in feces were assessed at the beginning and end of the trial. Among IBS symptoms scores, abdominal pain score was significantly reduced in BNR-H group. Lb. gasseri BNR17 was detected in all intake groups except placebo. In the preliminary study, Lb. gasseri BNR17 was confirmed to have probiotic properties.


Lactobacillus gasseri BNR17 Irritable bowel syndrome Probiotics 



This study was supported by a Bio-Synergy Research Project (2012M3A9C4048761) of the National Research Foundation funded by the Ministry of Science, ICT and Future Planning, Republic of Korea.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Wang JR, Xing ZQ, Tang W, Zheng YN, Wang YP. Isolation, identification, and potential probiotic characterization of one Lactococcus from Kefir grain. Food Sci Biotechnol 24: 1775–1780 (2015)CrossRefGoogle Scholar
  2. 2.
    Yao X, Yang YS, Cui LH, Zhao KB, Zhang ZH, Peng LH, Guo X, Sun G, Shang J, Wang WF, Feng J, Huang Q. Subtypes of irritable bowel syndrome on Rome III criteria: a multicenter study. J Gastroenterol Hepatol 27: 760–5 (2012)CrossRefPubMedGoogle Scholar
  3. 3.
    Jung HK, Kim YH, Park JY, Jang BH, Park SY, Nam MH, Choi MG. Estimating the burden of irritable bowel syndrome: analysis of a nationwide korean database. J Neurogastroenterol Motil 20: 242–52 (2014)CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    American College of Gastroenterology Task Force on Irritable Bowel S, Brandt LJ, Chey WD, Foxx-Orenstein AE, Schiller LR, Schoenfeld PS, Spiegel BM, Talley NJ, Quigley EM. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 104 Suppl 1: S1–35 (2009)PubMedGoogle Scholar
  5. 5.
    Brandt LJ, Bjorkman D, Fennerty MB, Locke GR, Olden K, Peterson W, Quigley E, Schoenfeld P, Schuster M, Talley N. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 97: S7–26 (2002)PubMedGoogle Scholar
  6. 6.
    Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 14: 581–7 (2011)CrossRefPubMedGoogle Scholar
  7. 7.
    Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104: 1033–49; quiz 1050 (2009)Google Scholar
  8. 8.
    Yun SI, Park HO, Kang JH. Effect of Lactobacillus gasseri BNR17 on blood glucose levels and body weight in a mouse model of type 2 diabetes. J Appl Microbiol 107: 1681–6 (2009)CrossRefPubMedGoogle Scholar
  9. 9.
    Jung SP, Lee KM, Kang JH, Yun SI, Park HO, Moon Y, Kim JY. Effect of Lactobacillus gasseri BNR17 on Overweight and Obese Adults: A Randomized, Double-Blind Clinical Trial. Korean J Fam Med 34: 80–9 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kang JH, Yun SI, Park HO. Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol 48: 712–4 (2010)CrossRefPubMedGoogle Scholar
  11. 11.
    Kang JH, Yun SI, Park MH, Park JH, Jeong SY, Park HO. Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS One 8: e54617 (2013)CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, Horowitz M. Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther 17: 1179–87 (2003)CrossRefPubMedGoogle Scholar
  13. 13.
    Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22: 387–94 (2005)CrossRefPubMedGoogle Scholar
  14. 14.
    Zimmerman J. Extraintestinal symptoms in irritable bowel syndrome and inflammatory bowel diseases: nature, severity, and relationship to gastrointestinal symptoms. Dig Dis Sci 48: 743–9 (2003)CrossRefPubMedGoogle Scholar
  15. 15.
    Takahashi H, Fujita T, Suzuki Y, Benno Y. Monitoring and survival of Lactobacillus gasseri SBT2055 in the human intestinal tract. Microbiol Immunol 50: 867–70 (2006)CrossRefPubMedGoogle Scholar
  16. 16.
    Ducrotte P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroentero 18: 4012–4018 (2012)CrossRefGoogle Scholar
  17. 17.
    Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J Nutr 140: 690S–7S (2010)CrossRefPubMedGoogle Scholar
  18. 18.
    Jankovic I, Sybesma W, Phothirath P, Ananta E, Mercenier A. Application of probiotics in food products-challenges and new approaches. Curr Opin Biotech 21: 175–181 (2010)CrossRefPubMedGoogle Scholar
  19. 19.
    Fujiwara S, Seto Y, Kimura A, Hashiba H. Establishment of orally-administered Lactobacillus gasseri SBT2055SR in the gastrointestinal tract of humans and its influence on intestinal microflora and metabolism. J Appl Microbiol 90: 343–52 (2001)CrossRefPubMedGoogle Scholar
  20. 20.
    Olivares M, Diaz-Ropero MA, Gomez N, Lara-Villoslada F, Sierra S, Maldonado JA, Martin R, Lopez-Huertas E, Rodriguez JM, Xaus J. Oral administration of two probiotic strains, Lactobacillus gasseri CECT5714 and Lactobacillus coryniformis CECT5711, enhances the intestinal function of healthy adults. Int J Food Microbiol 107: 104–11 (2006)CrossRefPubMedGoogle Scholar
  21. 21.
    Takagi A, Yanagi H, Ozawa H, Uemura N, Nakajima S, Inoue K, Kawai T, Ohtsu T, Koga Y. Effects of Lactobacillus gasseri OLL2716 on Helicobacter pylori-Associated Dyspepsia: A Multicenter Randomized Double-Blind Controlled Trial. Gastroenterol Res Pract 2016: 7490452 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Alok A, Singh ID, Singh S, Kishore M, Jha PC, Iqubal MA. Probiotics: A New Era of Biotherapy. Adv Biomed Res 6: 31 (2017)CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Andreasen AS, Larsen N, Pedersen-Skovsgaard T, Berg RM, Moller K, Svendsen KD, Jakobsen M, Pedersen BK. Effects of Lactobacillus acidophilus NCFM on insulin sensitivity and the systemic inflammatory response in human subjects. Br J Nutr 104: 1831–8 (2010)CrossRefPubMedGoogle Scholar

Copyright information

© The Korean Society of Food Science and Technology and Springer Science+Business Media B.V., part of Springer Nature 2017

Authors and Affiliations

  • Ji Yeon Kim
    • 1
  • Yeo Jin Park
    • 2
  • Hyo Jin Lee
    • 2
  • Min Young Park
    • 2
  • Oran Kwon
    • 2
    Email author
  1. 1.Department of Food Science and TechnologySeoul National University of Science and TechnologySeoulKorea
  2. 2.Department of Nutritional Science and Food ManagementEwha Womans UniversitySeoulKorea

Personalised recommendations